Needham & Company LLC restated their buy rating on shares of Nurix Therapeutics ( NASDAQ:NRIX – Get Rating ) in a research report report published on Friday morning, Benzinga reports. The firm currently has a $31.00 price objective on the stock. Several other equities research analysts have also weighed in on NRIX. Stifel Nicolaus dropped their price target on Nurix Therapeutics from $37.00 to $31.00 and set a buy rating on the stock in a research report on Tuesday, February 14th. Oppenheimer initiated coverage on shares of Nurix Therapeutics in a research note on Monday, February 27th.

https://www.dailypolitical.com/2023/04/17/nurix-therapeutics-nrix-buy-rating-reaffirmed-at-needham-company-llc.html

#dailypolitical